Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Aminocaproic Acid, Bleeding Complications Assessed

Leuk Lymphoma; ePub 2018 Feb 9; Juhl, Roddy, et al

Aminocaproic acid does not seem to lead to a high incidence of thromboembolic complications in people with hematologic malignancies, researchers concluded after conducting a retrospective study involving 109 individuals. Participants with hematologic malignancies had received aminocaproic acid to prevent/treat of thrombocytopenic hemorrhage. Investigators looked for thromboembolic complications confirmed by imaging studies. Among the results:

  • 5% of patients experienced thromboembolic complications; all were venous thromboses.
  • These patients had additional risk factors, such as central venous catheters.

The author noted that the concurrent risk factors may have played a role in thromboses.

Citation:

Juhl R, Roddy J, Wang T, Li J, Elefritz J. Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. [Published online ahead of print February 9, 2018]. Leuk Lymphoma. doi:10.1080/10428194.2018.1434882.

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Bleeding Disorders

Durable responses for hemophilia A gene therapy, High K et al. ASH 2018, Abstract 487

A clot lysis contradiction with mild bleeding, Vries MJA et al. Thromb Res. 2018 Dec 4. doi: 10.1016/j.thromres.2018.12.004

Factor VIII inhibitors seen in some patient subgroups, not others, Gangadharan B et al. ASH 2018, Poster 3774

Could thrombin generation be a better biomarker?, Nossair F et al. ASH 2018, Poster 3788

Novoeight looks safe in hemophilia A extension trial, Lentz SR et al. Haemophilia. 2018 Nov;24(6):e391-e394